Washington hospital covid-19 Merck Washington

Merck COVID-19 pill: FDA panel to review safety data of molnupiravir

Reading now: 784
www.fox29.com

WASHINGTON - An influential panel of outside advisers to the U.S. Food and Drug Administration are scheduled to meet Tuesday to review safety data of an experimental COVID-19 pill developed by Merck.The FDA’s Antimicrobial Drugs Advisory Committee, which is scheduled to meet from 9 a.m.

to 5 p.m. ET, is made up of academics and other experts who will weigh in on its safety and effectiveness and vote on whether to recommend its use for certain groups.

The FDA isn’t required to follow the group’s advice.All COVID-19 drugs currently authorized by the FDA require an injection or IV, which limits their use.

Merck asked the FDA to authorize the drug, known as molnupiravir, in October. If approved, Merck’s coronavirus antiviral would be the first.

Read more on fox29.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA